Edwin DeJesus, MD, FACP, FIDSA
Medical DirectorDr. Edwin DeJesus, MD, FACP, FIDSA is the Medical Director of the OIC Inspired. He obtained his medical degree from the University of Puerto Rico, School of Medicine, and completed his Internal Medicine training and Infectious Disease fellowship at the Medical College of Pennsylvania in Philadelphia. Dr. DeJesus is board-certified in Infectious Diseases and holds certification as an HIV Specialist through the American Academy of HIV Medicine (AAHIVM).
With over 25 years of experience, Dr. DeJesus has dedicated his career to caring for HIV and hepatitis infected patients. He serves as the Principal Investigator for the OIC research department, leading Phase I-IV clinical trials focused on improving prevention, management, and treatment of infectious conditions including, HIV vaccines and cure studies. Recently, Dr. DeJesus has played an active role with the NIH in Covid-19 vaccines and treatment.
Dr. DeJesus has amassed an impressive bibliography of over 100 recent publications related to his research. He is highly regarded in the medical community and has presented his research findings at numerous international conferences, including the IAS, ICCAC, CROI, amongst many others. As a respected public educator, he has been a guest speaker at various medical conferences and institutions, sharing his expertise on HIV, hepatitis, and infectious diseases.
Beyond his clinical and research work, he is an assistant professor at the University of Central Florida (UCF) College of Medicine. Dr. DeJesus is deeply committed to his patients and community. He has initiated free HIV testing programs, opened the first PrEP clinic in Orlando, maintains strong relationships with Central Florida non-profit organizations, and has contributed medical columns to local publications.
Dr. DeJesus’s contributions to the medical field and dedication to patient care have earned him numerous accolades and recognition. He has been featured as one of Orlando’s Top Doctors by Orlando Magazine for the past ten years and was named one of the 25 most influential Hispanic individuals in Central Florida by the Hispanic Chambers of Commerce.
With his expertise, research endeavors, and commitment to community outreach, Dr. Edwin DeJesus continues to make a significant impact in the field of infectious diseases, comprehensive healthcare for the sexually active adult, and the lives of his patients.
Professional Affiliations
- Fellow Infectious Disease Society of America
- Clinical Affairs Committee, Infectious Disease Society
- HIVMA, Board of Directors, Infectious Disease Chair
- International AIDS Society
- American Academy of HIV Medicine
- American Academy Of HIV Medicine Core Curriculum Faculty
- American College of Physicians Fellowship
- HIV Medical Association
- Infectious Disease Society of America
- Florida Infectious Diseases Society Member
- American College of Physicians Member
- American Medical Association
- HIV Specialist through the American Academy of HIV Medicine
Publications/Presentations
- Pitavastatin to Prevent Cardiovascular Disease in HIV Infection
- Racial/ethnic disparities in HIV care outcomes among insured patients at a large urban sexual health clinic
- Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials
- Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting.
- Rolle CP, Castano J, Nguyen V, Patel K, Hinestrosa F, DeJesus E. Antivir Ther. 2023 Feb;28(2):13596535231163703. doi: 10.1177/13596535231163703. PMID: 36896821
- Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial.
- Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.
- Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1.
- Long-Term Efficacy, Safety, and Durability of Cabotegravir and Rilpivirine as 2-Drug Oral Maintenance Therapy After 6 Years of Study.
- Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial.
- Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.
- Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV.
- The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy.
- Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial.
- Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV.
- Clinical outcomes of HIV-1 infected patients switched from complex multi-tablet regimens to tenofovir alafenamide based single-tablet regimens plus a boosted protease inhibitor in a real-world setting.
- Determinants of pre-exposure prophylaxis (PrEP) persistence in a high-risk population in Central Florida.
- Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus-1.
- Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
- Clinical outcomes of once-daily darunavir in treatment-experienced patients with darunavir resistance-associated mutations through 48 weeks of treatment.
- Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.
- Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection.
- A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 Infection.
- Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial.